Telo Genomics (Germany) Performance
| 3D0A Stock | EUR 0.04 0.01 46.67% |
Telo Genomics holds a performance score of 14 on a scale of zero to a hundred. The entity has a beta of 0.18, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Telo Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Telo Genomics is expected to be smaller as well. Use Telo Genomics Corp semi deviation, coefficient of variation, jensen alpha, as well as the relationship between the downside deviation and information ratio , to analyze future returns on Telo Genomics Corp.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Telo Genomics Corp are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, Telo Genomics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3.6 M | |
| Total Cashflows From Investing Activities | -25.2 K | |
| Free Cash Flow | -1.8 M |
Telo |
Telo Genomics Relative Risk vs. Return Landscape
If you would invest 7.00 in Telo Genomics Corp on November 28, 2024 and sell it today you would lose (2.60) from holding Telo Genomics Corp or give up 37.14% of portfolio value over 90 days. Telo Genomics Corp is generating 7.6417% of daily returns assuming 42.1681% volatility of returns over the 90 days investment horizon. Simply put, majority of traded equity instruments are less risky than Telo on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Telo Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telo Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Telo Genomics Corp, and traders can use it to determine the average amount a Telo Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1812
| Best Portfolio | Best Equity | 3D0A | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 42.17 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Telo Genomics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telo Genomics by adding it to a well-diversified portfolio.
Telo Genomics Fundamentals Growth
Telo Stock prices reflect investors' perceptions of the future prospects and financial health of Telo Genomics, and Telo Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telo Stock performance.
| Return On Equity | -0.78 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 13.04 M | |||
| Shares Outstanding | 59.42 M | |||
| Price To Book | 8.88 X | |||
| EBITDA | (2.05 M) | |||
| Cash And Equivalents | 1.96 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 40 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (1.79 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 2.83 M | |||
About Telo Genomics Performance
By analyzing Telo Genomics' fundamental ratios, stakeholders can gain valuable insights into Telo Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Telo Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Telo Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada. TELO GENOMICS operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange.Things to note about Telo Genomics Corp performance evaluation
Checking the ongoing alerts about Telo Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Telo Genomics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telo Genomics Corp is way too risky over 90 days horizon | |
| Telo Genomics Corp has some characteristics of a very speculative penny stock | |
| Telo Genomics Corp appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (2.11 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Telo Genomics Corp has accumulated about 1.96 M in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. |
- Analyzing Telo Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telo Genomics' stock is overvalued or undervalued compared to its peers.
- Examining Telo Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telo Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telo Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telo Genomics' stock. These opinions can provide insight into Telo Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Telo Stock analysis
When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |